Langer accepts $450K Kyoto prize; Isis raises $425M; Boehringer passes on Karolinska antibody;

@FierceBiotech: $AMGN and $AZN psoriasis drug beats blockbuster Stelara ($JNJ) in head-to-head trial. Report | Follow @FierceBiotech

@JohnCFierce: Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device. News | Follow @JohnCFierce

@DamianFierce: Hep C market share optimism has $ABBV up. Also, cab ads. Picture | Follow @DamianFierce

> MIT Professor Robert Langer has accepted the prestigious Kyoto Prize, which comes with $450,000. Story

> Isis Pharmaceuticals ($ISIS) priced $425 million in senior notes this morning. Its shares are down 3% in early trading. Release

> In a fresh setback for Karolinska Development, Boehringer Ingelheim has chosen not to exercise its option on Athera Biotechnologies' cardiovascular antibody. Athera is a Karolinska portfolio company. Release

> Australia's Neuren Pharmaceuticals is touting positive Phase II data for Rett syndrome, which sent shares up 53% (or 4 cents, depending on how you're counting). Release (PDF)

Medical Device News

@FierceMedDev: ICYMI yesterday: With fresh infusion of cash in tow, Thync rolls out wearable, noninvasive device to elevate mood. Article | Follow @FierceMedDev

@VarunSaxena2: Aethlon to begin U.S. testing for its Ebola treatment device by year end. More | Follow @VarunSaxena2

@EmilyWFierce: Mark your calendars: EU Commission will decide by Nov. 28 whether or not to approve $MDT's $43B deal for $COV. More  | Follow @EmilyWFierce

> Medtronic borrows $16B to cover rising costs of Covidien deal. Article

> FDA clears first patient-specific spinal rod. More

Pharma News

@FiercePharma: Top-read in #pharma #manufacturing Tues: Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. More | Follow @FiercePharma

@EricPFierce: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More  | Follow @EricPFierce

@CarlyHFierce: Mylan visits Disney Parks for a little EpiPen marketing magic. More | Follow @CarlyHFierce

> WSJ: Pfizer spinoff Zoetis might be Valeant's backup plan if Allergan bid fails. Story

> Italy, the land of pharma plenty, boasts three hidden billionaires in its ranks. Article

> Winners and losers at AASLD? Check out Merck, AbbVie, Gilead and J&J data. More

Drug Delivery News

> Drug-loaded milk could offer oral HIV/AIDS prevention to children. Story

> Alnylam adds two RNAi programs to its hepatitis pipeline. Article

> Arrowhead's midstage hep B data shows promise for RNA-based 'functional cure.' News

> FDA clears syringe that prevents needlestick injuries. News

> Nasal spray for migraines under development. Story

Diagnostics News

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Story

> Quest CEO says 'no' to CRO. Report

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Item

> Scientists developing machine-based algorithm for heart failure and emphysema Dx. Article

Pharma Marketing News

> Under siege by Biogen's new long-acting Eloctate, Baxter's Advate stands its ground. Report

> Missing the old pharma swag? Take a trip down memory lane. Article

> Will GLP market growth save Novo's Victoza from Lilly's new Trulicity? More

> Contrave demand swamps Takeda's direct-delivery discount program. Story

> Mylan visits Disney Parks for a little EpiPen marketing magic. Article

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.